-
公开(公告)号：US20240123092A1
公开(公告)日：2024-04-18
申请号：US18468674
申请日：2023-09-15
Applicant: NATIONAL CANCER CENTER
Inventor： Yong-Doo CHOI , Ji-Su Kim , Hyun Jin Kim
CPC classification number: A61K49/0056 , A61K41/0071 , A61K47/65 , A61K49/0082 , A61K49/0086 , A61P35/00
Abstract: Provided is a conjugate for photodynamic diagnosis or treatment in which a peptide binds with a photosensitizer via an intracellularly degradable linkage, and a composition for photodynamic diagnosis or treatment including the same. The conjugate generates no fluorescent signal and reactive oxygen in normal tissues or during the circulation in the blood by quenching a fluorescent signal and reactive oxygen generation ability of the photosensitizer. After the conjugate is selectively absorbed into target cells, a linker is degraded in cells to increase the distance between tryptophan included in the peptide and the photosensitizer, and the quenching action is terminated to generate a strong fluorescence signal and induce active generation of reactive oxygen. The conjugate has high tissue permeability, shows a high photodynamic therapeutic effect in only target cells while being safe in normal cells, and can obtain a good diagnostic image having a high ratio of target signal to background.
-
公开(公告)号：US07682603B2
公开(公告)日：2010-03-23
申请号：US10777552
申请日：2004-02-12
Applicant: Daniel A. Hammer , Michael J. Therien , Paiman Peter Ghoroghchian
Inventor： Daniel A. Hammer , Michael J. Therien , Paiman Peter Ghoroghchian
CPC classification number: A61K49/0036 , A61K49/0021 , A61K49/0041 , A61K49/0086
Abstract: The instant invention concerns compositions comprising polymersomes, visible or near infrared emissive agents, and optionally a targeting moiety associated with a surface of the polymersome. The invention also relates to use of these compositions in the treatment of disease and in imaging methodology.
Abstract translation: 本发明涉及包含聚合物单体，可见或近红外发射剂和任选的与聚合物的表面相关的靶向部分的组合物。 本发明还涉及这些组合物在治疗疾病和成像方法中的用途。
-
公开(公告)号：US20240299302A1
公开(公告)日：2024-09-12
申请号：US18659243
申请日：2024-05-09
Applicant: SL BIGEN, INC.
Inventor： Yong Song GHO , Dong-Sic CHOI , Gyeongyun GO
IPC: A61K9/127 , A61K9/50 , A61K9/51 , A61K31/704 , A61K31/713 , A61K33/26 , A61K38/46 , A61K47/50 , A61K48/00 , A61K49/00
CPC classification number: A61K9/1273 , A61K9/5068 , A61K9/5089 , A61K9/5192 , A61K31/704 , A61K31/713 , A61K33/26 , A61K38/465 , A61K47/50 , A61K48/00 , A61K49/00 , A61K49/0067 , A61K49/0086 , C12Y301/27005
Abstract: Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances. In addition, the cell membrane-derived nanovesicles loaded with therapeutic or diagnostic substances and a method of preparing the nanovesicles may be used in vitro or in vivo for therapeutic or diagnostic purposes, or for experimental use.
-
Patent Agency Ranking
4.发明申请NANO-PARTICLES FOR INTERNAL RADIATION THERAPY OF INVOLVED AREA, AND THERAPY SYSTEM 审中-公开涉及领域内部辐射治疗的纳米颗粒和治疗系统公开(公告)号：US20150031988A1
公开(公告)日：2015-01-29
申请号：US14344562
申请日：2012-09-12
Applicant: Eri Takeuchi , Isao Hara , Ryo Yamahara , Eiichi Ozeki , Shunsaku Kimura , Kensuke Kurihara
Inventor： Eri Takeuchi , Isao Hara , Ryo Yamahara , Eiichi Ozeki , Shunsaku Kimura , Kensuke Kurihara
CPC classification number: A61K51/1244 , A61B5/055 , A61B5/061 , A61B5/0813 , A61B6/037 , A61B6/12 , A61B6/4258 , A61B6/485 , A61B6/508 , A61B8/085 , A61B18/0218 , A61B18/1477 , A61B18/1815 , A61B2018/0293 , A61B2018/1869 , A61K49/0054 , A61K49/0086 , A61K51/06 , A61K51/12 , A61K51/1237 , A61K2123/00 , A61N5/10 , A61N2005/1011 , A61N2005/1021 , A61N2005/1052 , A61N2005/1098
Abstract: The present invention provides a therapeutic system that is widely applicable to general solid cancers, can achieve both a reduction in side effects of cancer therapy and suppression of cancer recurrence and metastasis, and requires no expensive drug such as an antibody; and a nanoparticle for internal radiation therapy. A system for internal radiation therapy of a vascular lesion site comprising: a device comprising a means for acquiring image data showing a position of a vascular lesion site, and a means for positioning a needle, which should be punctured into the vascular lesion site, at the vascular lesion site based on the image data; and a nanoparticle comprising an amphiphilic block polymer comprising a hydrophilic block having a sarcosine unit and a hydrophobic block having a lactic acid unit, and a substance labeled with a β-ray emitting nuclide. The nanoparticle for internal radiation therapy.
Abstract translation: 本发明提供广泛适用于一般实体癌症的治疗系统，可以实现癌症治疗的副作用降低和癌症复发和转移的抑制，并且不需要昂贵的药物如抗体; 和用于内部放射治疗的纳米颗粒。 一种用于血管损伤部位的内部放射治疗的系统，包括：装置，包括用于获取显示血管病变部位的位置的图像数据的装置，以及用于定位针头的装置，其应穿刺入血管损伤部位， 基于图像数据的血管病变部位; 以及包含两亲性嵌段聚合物的纳米颗粒，所述两亲性嵌段聚合物包含具有肌氨酸单元的亲水性嵌段和具有乳酸单元的疏水性嵌段，以及用发射核素发射的核素标记的物质。 用于内部放射治疗的纳米颗粒。
-
公开(公告)号：US12011505B2
公开(公告)日：2024-06-18
申请号：US17212131
申请日：2021-03-25
Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
Inventor： Yong Song Gho , Dong-Sic Choi , Gyeongyun Go
IPC: A61K9/127 , A61K9/50 , A61K9/51 , A61K31/704 , A61K31/713 , A61K33/26 , A61K38/46 , A61K47/50 , A61K48/00 , A61K49/00
CPC classification number: A61K9/1273 , A61K9/5068 , A61K9/5089 , A61K9/5192 , A61K31/704 , A61K31/713 , A61K33/26 , A61K38/465 , A61K47/50 , A61K48/00 , A61K49/00 , A61K49/0067 , A61K49/0086 , C12Y301/27005
Abstract: Disclosed are cell membrane-derived nanovesicles, a method of preparing the nanovesicles, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles may prevent potential adverse effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivering therapeutic or diagnostic substances are removed from the nanovesicles. In addition, as the nanovesicles may be targeted to specific cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues, while delivery of the substances may be inhibited. Therefore, the nanovesicles may alleviate suffering and inconvenience of patients by reducing adverse effects of therapeutic substances and by improving efficacy of the substances. In addition, the cell membrane-derived nanovesicles loaded with therapeutic or diagnostic substances and a method of preparing the nanovesicles may be used in vitro or in vivo for therapeutic or diagnostic purposes, or for experimental use.
-
公开(公告)号：US20050019265A1
公开(公告)日：2005-01-27
申请号：US10777552
申请日：2004-02-12
Applicant: Daniel Hammer , Michael Therien , Paiman Ghoroghchian
Inventor： Daniel Hammer , Michael Therien , Paiman Ghoroghchian
CPC classification number: A61K49/0036 , A61K49/0021 , A61K49/0041 , A61K49/0086
Abstract: The instant invention concerns compositions comprising polymersomes, visible or near infrared emissive agents, and optionally a targeting moiety associated with a surface of the polymersome. The invention also relates to use of these compositions in the treatment of disease and in imaging methodology.
Abstract translation: 本发明涉及包含聚合物单体，可见或近红外发射剂和任选的与聚合物的表面相关的靶向部分的组合物。 本发明还涉及这些组合物在治疗疾病和成像方法中的用途。
-
公开(公告)号：US12102715B1
公开(公告)日：2024-10-01
申请号：US17532795
申请日：2021-11-22
Applicant: Verily Life Sciences LLC
Inventor： Kimberly Kam , Zhan Wang , Stephen Morton , Nicole Peck
IPC: A61K9/127 , A61K31/7088 , A61K38/02 , A61K39/395 , A61K47/42 , A61K47/69 , A61K49/00 , A61P39/06 , B01J13/22
CPC classification number: A61K9/1271 , A61K9/1277 , A61K31/7088 , A61K38/02 , A61K39/395 , A61K47/42 , A61K47/6913 , A61K49/0032 , A61K49/0086 , A61P39/06 , B01J13/22 , Y10S977/773 , Y10S977/906 , Y10S977/907
Abstract: Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.
-
公开(公告)号：US20180036240A1
公开(公告)日：2018-02-08
申请号：US15545398
申请日：2015-08-24
Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
Inventor： Yong Song GHO , Dong-Sic CHOI , Gyeongyun GO
IPC: A61K9/127 , A61K38/46 , A61K33/26 , A61K49/00 , A61K31/713 , A61K31/704
CPC classification number: A61K9/1273 , A61K9/5068 , A61K9/5089 , A61K9/5192 , A61K31/704 , A61K31/713 , A61K33/26 , A61K38/465 , A61K47/50 , A61K48/00 , A61K49/00 , A61K49/0067 , A61K49/0086 , C12Y301/27005
Abstract: The present invention relates to cell membrane-derived nanovesicles, a method of preparing the same, and a pharmaceutical composition and a diagnostic kit using the nanovesicles. The cell membrane-derived nanovesicles according to the present invention may prevent the occurrence of potential side effects because intracellular materials (e.g., genetic materials and cytosolic proteins) unnecessary for delivery of therapeutic or diagnostic substances are removed from the nanovesicles. In addition, since the nanovesicles may be targeted to the specific types of cells or tissues, therapeutic or diagnostic substances may be predominantly delivered to the targeted cells or tissues while delivery of therapeutic or diagnostic substances to untargeted sites may be inhibited. Therefore, when the cell membrane-derived nanovesicles are applied to disease treatment, the side effects of therapeutic substances such as drugs may be reduced, so that suffering and inconvenience of patients may be alleviated during the course of treating diseases, and therapeutic efficacy may be improved. In addition, the cell membrane-derived nanovesicles of the present invention, in which substances for the treatment or diagnosis of diseases are loaded, and a method of preparing the nanovesicles may be used in vitro or in vivo for therapeutic or diagnostic purposes, or for experimental use.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.021 seconds)
